Mostrar el registro sencillo del ítem
dc.contributor.author
Rey, María Verónica
dc.contributor.author
Molina, Luis
dc.contributor.author
Recinos, Byron
dc.contributor.author
Paz, Bezner
dc.contributor.author
Rovelo, Mauricio
dc.contributor.author
Rodriguez Elias, Fanny Elizabeth
dc.contributor.author
Calderón, José
dc.contributor.author
Arellano, Arturo
dc.contributor.author
Pérez Lloret, Santiago
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.date.available
2020-01-08T19:09:34Z
dc.date.issued
2018-09
dc.identifier.citation
Rey, María Verónica; Molina, Luis; Recinos, Byron; Paz, Bezner; Rovelo, Mauricio; et al.; Movement Disorders After Exposure to Antipsychotic Drugs in Patients With Depressive Disorders; Lippincott Williams; Clinical Neuropharmacology; 41; 5; 9-2018; 177-180
dc.identifier.issn
0362-5664
dc.identifier.uri
http://hdl.handle.net/11336/93985
dc.description.abstract
Objectives The aims of the study were to explore the frequency of movement disorders (MDs) in depressive patients exposed to antipsychotic drugs (APDs) and to compare it with nonexposed depressive patients and APDs-treated schizophrenic patients. Methods Four hundred fifty-two depressive patients not exposed to APDs (group A), 156 depressives exposed to APDs (group B), and 75 patients with schizophrenia on APDs (group C) were recruited. Presence of MDs was explored by the Simpson-Angus and UKU scales (Registration: NCT02409823). Results Movement disorders were observed in 5%, 9%, and 13% of patients in groups A to C, respectively (P < 0.001, χ2 for linear trend). A logistic multivariate analysis revealed that male sex (odds ratio = 2.26, 95% confidence interval = 1.13–4.49, P < 0.01), exposure to first-generation (vs second-generation) APDs (odds ratio = 5.71, 95% confidence interval = 2.08–15.66, P < 0.01), and exposure to lithium (odds ratio = 3.99, 95% confidence interval = 1.74–9.14, P < 0.01) were independently and significantly associated with MDs. Conclusions Male sex, use first-generation APDs, and exposure to lithium were associated with MDs in depression. Therefore, caution is advised with the use of these drugs in depressive patients. Prospective studies are needed to confirm these results.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Lippincott Williams
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
ANTIPSYCHOTIC DRUGS
dc.subject
BIPOLAR DEPRESSIVE DISORDER
dc.subject
DRUG-INDUCED MOVEMENT DISORDERS
dc.subject
MAJOR DEPRESSIVE DISORDER
dc.subject
PHARMACOVIGILANCE
dc.subject
SCHIZOPRHENIA
dc.subject.classification
Neurología Clínica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Medicina Clínica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Movement Disorders After Exposure to Antipsychotic Drugs in Patients With Depressive Disorders
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2019-10-23T14:40:45Z
dc.journal.volume
41
dc.journal.number
5
dc.journal.pagination
177-180
dc.journal.pais
Estados Unidos
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.journal.ciudad
Philadelphia
dc.description.fil
Fil: Rey, María Verónica. Etymos Consulting Group; Argentina
dc.description.fil
Fil: Molina, Luis. Clínica de Especialidades Altamira; Nicaragua
dc.description.fil
Fil: Recinos, Byron. Universidad San Carlos de Guatemala; Guatemala
dc.description.fil
Fil: Paz, Bezner. Hospital Juan de Dios de San Pedro;
dc.description.fil
Fil: Rovelo, Mauricio. Instituto de Salud Mental; Honduras
dc.description.fil
Fil: Rodriguez Elias, Fanny Elizabeth. Colonia Médica; El Salvador
dc.description.fil
Fil: Calderón, José. Clínica de la Conducta; Panamá
dc.description.fil
Fil: Arellano, Arturo. Drugtech, Corporación Farmacéutica Recalcine; Costa Rica
dc.description.fil
Fil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiológicas; Argentina
dc.journal.title
Clinical Neuropharmacology
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1097/WNF.0000000000000300
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://insights.ovid.com/crossref?an=00002826-201809000-00006
Archivos asociados